Introduction: In the management of type 2 diabetes, insulin is often started late, when there is failure to achieve good control on maximum oral agents. Clinical inertia to insulin initiation and intensification is widely prevalent in our local setting resulting in poor control of diabetes. This study looked into a stepwise insulin combinations treatment algorithm used in an Endocrinology referral clinic at the University of Santo Tomas Hospital (USTH). It aimed to demonstrate the clinical course of the patients , determine the degree of HbA1c reduction, and show the associated extent of hypoglycemia and weight gain.

Methods: This is a retrospective chart review of 104 patients that used the following stepwise treatment: Oral regimen; Regimen A: basal+oral; Regimen B: basal+premeal bolus TID±oral; Regimen C: premixed aspart 70/30 or lispro 75/25 TID or BID with prelunch bolus, ± oral; Regimen D: premixed 70/30 BID+premeal bolus TID ± oral; Regimen E: premixed 70/30 BID+premeal bolus TID+basal ±oral. All received automatic snacking two hours after main meals to prevent hypoglycemia. Patients were educated on proper diet and exercise. Data was analyzed using paired t-test, frequencies and percentages.

Results: Most ended on the intensive insulin regimens D 57(55%) , and E 18 (17%). Significant HbA1c reduction was demonstrated as follows: Regimen A (n=8):1.376±0.919 (p=0.000), Regimen B (n=18):2.320±2.177 (p=0.000), Regimen D (n=57):2.197±2.158 (p=0.000), Regimen E (n=18):2.684±1.689 (p =0.000). Overall mean weight gain was 1.070 ± 11.435 kg (p=0.335). Ten, non-severe hypoglycemia events were reported.

Conclusion: The use of this stepwise insulin combinations treatment algorithm exerted significant HbA1c reduction, with minimal events of hypoglycemia, and statistically insignificant weight gain. Hence, this is a feasible tool that may be used as a guide for intensification of insulin treatment.

Keywords: Diabetes Mellitus Type 2, insulin combinations, HbA1c reduction

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine, 329: 977- 986, 1993.
2. King P, Peacock I, Donelly R. The UK Prospective Diabetes Study (UKPDS): Clinical and Therapeutic Implications for Type 2 Diabetes. British Journal of Clinical Pharmacology, 48(5): 643- 648, 1999.
3. Nathan DM, Buse JB, Davidson MB. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy, A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 32(1):193-203, 2009.
4. Riddle MC, Rosenstock J, Gerick J. The Treat-to-Target Trial, Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 26(11): 3080- 3086, 2003.
5. Vinagre I, Sanchez-Hernandez J, Sanchez-Quesada JL. Switching to basal-bolus insulin therapy is effective and safe in long term Type 2 Diabetic patients inadequately controlled with other insulin regimens. Endocronologia y Nutricion, 60 (5): 249- 253, 2013.
6. Bowering K, Reed VA, Felicio JS, Landry J, Ji L, Oliviera J. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycemic control on oral anti-hyperglycemic medication: results of the PARADIGM study. Diabetes Medicine, 29 (9): e263-272, 2012.
7. Laplano ER, Mercado-Asis LB. Sustainable Glycemic Control with Combination Insulin Therapy of Biphasic Insulin Plus Rapid Acting Insulin Mimicking Physiologic Insulin Secretion in Type 2 Diabetes. Philippine Journal of Internal Medicine, 50(3): 1-6, 2012.
8. Fonseca VA. Defining and Characterizing the Progression of Type 2 Diabetes. Diabetes Care. 32: S151-S156, 2009.
9. Seaquist ER, Anderson J, Childs B, Cryer P. Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and the Endocrine Society. Journal of Clinical Endocrinology and Metabolism, 98(5):1845–1859, 2013.
10. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycemic agents (APOLLO): an open randomized controlled trial. Lancet. 371:1073-1084, 2008.
11. Barnard K, Batch BC, Lein LF. Subcutaneous Insulin: A Guide for Dosing Regimens in the Hospital. Glycemic Control in the Hospitalized Patient, Edited by Lein LF, Cox ME, Feinglos MN, Corsino L, Springer New York, 2011, P10.
12. Petznick A; Insulin Management of Type 2 Diabetes Mellitus. American Family Physician, 84(2): 183-190, 2011.
13. Fritsche A, Larbig M, Owens G, Haring HU. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab. 12:115-123, 2010.
14. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K. Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target. Diabetes Care. 34 (2):510-517, 2011.
15. Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R. Attainment of glycemic goals in type 2 diabetes with once-twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes, Obesity and Metabolism, 8(1): 58-66, 2006.
16. Lorenzo ZG, Mercado-Asis LB. Automatic Snacking Prevents Hypoglycemia Among Outpatient Type 2 Diabetic Patients on Intensive Insulin Therapy. Philippine Journal of Internal Medicine,49 (2): 57-60, 2011.
17. Sheperd PR, Kahn BB. Glucose transporters and insulin action: implications for insulin resistance and Diabetes Mellitus. N. Engl. J. Med. 341: 248-257, 1999.
18. Kahn BB, Flier JS. Obesity and Insulin Resistance. The Journal of Clinical Investigation, 106(4): 473-81, 2000.
19. Patti ME, Kahn CR. Lessons from transgenic and knock-out animals about noninsulin-dependent diabetes mellitus. Trends Endocrinol. Metab, 7: 311-319, 1996
20. Fink RI, Kolterman OG, Griffin J. Mechanisms of Insulin Resistance in Aging. The Journal of Clinical Investigation, 71(6): 1523-1535, 1983.
21. Veema M, Paneri S, Badi P, Raman PG. Effect of Increasing Duration of Diabetes Mellitus Type 2 On Glycated Hemoglobin and Insulin Sensitivity. Indian Journal of Clinical Biochemistry, 21(1): 142-146, 2006.
22. Meneghini LF. Early Insulin Treatment in Type 2 Diabetes, What are the pros? Diabetes Care, 32: S266-S269, 2009.
23. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical Inertia in People with Type 2 Diabetes. Diabetes Care, 36: 3411-3417, 2013.
24. Mayfield JA, White RD. Insulin Therapy for Type 2 Diabetes: Rescue, Augmentation, and Replacement of Beta-Cell Function. American Family Physician, 70: 489-500, 2004.
25. Nesher R, Cerasi E. Section 2: Biphasic Insulin Release: Pools and Signal Modulation. Modeling Phasic Insulin Release, Immediate and Time-Dependent Effects of Glucose. Diabetes, 51: S53-S59, 2002.
26. Raz I, Mosenzon O. Early Insulinization to Prevent Diabetes Progression. Diabetes Care, 36: S190-S197, 2013.
27. Owens DR. Clinical Evidence for the Earlier Initiation of Insulin Therapy in Type 2 Diabetes. Diabetes Technology and Therapeutics,15(9): 776-785, 2013.
28. Reznik Y, Cohen O, Aronson R, Conget I, Runzis S, Castaneda J, Lee SW. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomized open-label controlled trial. Lancet 384 (9950): 1265- 1272, 2014.
29. Paty BW. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes. Canadian Journal of Diabetes 39:S155-S159, 2015.
30. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837-853, 1998.
31. Russel-Jones D, Khan R. Insulin-associated weight gain in diabetes—causes, effects and coping strategies. Diabetes Obes Metab , 9(6):799-812, 2007.